In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania
Authors:
- Estela Melcón-FernándezEstela Melcón-Fernández
- Giulio GalliGiulio Galli
- Rafael Balaña-FouceRBRafael Balaña-Fouce
- Nerea García-FernándezNGNerea García-Fernández
- María Martínez-ValladaresMaría Martínez-Valladares
- Rosa M. RegueraRRRosa M. Reguera
- Carlos García-EstradaCarlos García-Estrada
- Yolanda Pérez-PertejoYPYolanda Pérez-Pertejo
Open Access
- 25 January 2024
- journal article
- research article
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 9 (2) , 30
Abstract
One of the major drawbacks of current treatments for neglected tropical diseases is the low safety of the drugs used and the emergence of resistance. Leishmaniasis is a group of neglected diseases caused by protozoa of the trypanosomatidae family that lacks preventive vaccines and whose pharmacological treatments are scarce and unsafe. Combination therapy is a strategy that could solve the above-mentioned problems, due to the participation of several mechanisms of action and the reduction in the amount of drug necessary to obtain the therapeutic effect. In addition, this approach also increases the odds of finding an effective drug following the repurposing strategy. From the previous screening of two collections of repositioning drugs, we found that pyrvinium pamoate had a potent leishmanicidal effect. For this reason, we decided to combine it separately with two clinically used leishmanicidal drugs, miltefosine and paromomycin. These combinations were tested in axenic amastigotes of Leishmania infantum obtained from bone marrow cells and in intramacrophagic amastigotes obtained from primary cultures of splenic cells, both cell types coming from experimentally infected mice. Some of the combinations showed synergistic behavior, especially in the case of the combination of pyrvinium pamoate with paromomycin, and exhibited low cytotoxicity and good tolerability on intestinal murine organoids, which reveal the potential of these combinations for the treatment of leishmaniasis.Keywords
Funding Information
- “ESF Investing in your future” (PRE2021–096909)
- University of Leon (PRE2021–096909)
This publication has 57 references indexed in Scilit:
- Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled TrialPLOS Neglected Tropical Diseases, 2012
- Bright and stable near-infrared fluorescent protein for in vivo imagingNature Biotechnology, 2011
- A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific HitPLOS Neglected Tropical Diseases, 2011
- Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized TrialPLOS Neglected Tropical Diseases, 2010
- NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping SicknessPLOS Neglected Tropical Diseases, 2010
- New anti-tuberculosis agents amongst known drugsTuberculosis, 2009
- Non-competitive androgen receptor inhibition in vitro and in vivoProceedings of the National Academy of Sciences, 2009
- Efficacy of Pyrvinium Pamoate against Cryptosporidium parvum Infection In Vitro and in a Neonatal Mouse ModelAntimicrobial Agents and Chemotherapy, 2008
- Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in Leishmania donovani PromastigotesAntimicrobial Agents and Chemotherapy, 2007
- Fluorinated analogues of L-ornithine are powerful inhibitors of ornithine decarboxylase and cell growth of Leishmania infantum promastigotesLife Sciences, 1994